An in vivo murine model of rosiglitazone use in pregnancy

Fertility and Sterility

Volumn 86, Issue 4 SUPPL., 2006, Pages 1074-1079

  Klinkner, Denise B ^a   Lim, Hyun J ^a   Strawn Jr , Estil Y ^a   Oldham, Keith T ^a   Sander, Tara L ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

diabetes mellitus type 2; polycystic ovary syndrome; pregnancy; Rosiglitazone

Indexed keywords

ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLASTOCYST; BODY WEIGHT; CELL CULTURE; CONTROLLED STUDY; DRUG SAFETY; EMBRYO; EMBRYO DEVELOPMENT; FEMALE; MORPHOLOGY; MOUSE; NEWBORN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY POLYCYSTIC DISEASE; PHENOTYPE; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; TIME SERIES ANALYSIS;

ANIMALS; ANIMALS, NEWBORN; BLASTOCYST; COCULTURE TECHNIQUES; FEMALE; LITTER SIZE; MICE; MICE, INBRED ICR; MICE, INBRED STRAINS; PREGNANCY; PREGNANCY, ANIMAL; THIAZOLIDINEDIONES; TISSUE CULTURE TECHNIQUES; WEIGHT GAIN;

EID: 33748916017     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2006.03.024     Document Type: Article

References (49)

1. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270 (1995) 12953-12956
2. Nestler J.E., Stovall D., Akhter N., Iuorno M.J., and Jakubowicz D.J. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril 77 (2002) 209-215
3. Barbieri R.L., Makris A., Randall R.W., Daniels G., Kistner R.W., and Ryan K.J. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 62 (1986) 904-910
4. Nestler J.E., Powers L.P., Matt D.W., Steingold K.A., Plymate S.R., Rittmaster R.S., et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 72 (1991) 83-89
5. Belli S.H., Graffigna M.N., Oneto A., Otero P., Schurman L., and Levalle O.A. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril 81 (2004) 624-629
6. Physicians' Desk Reference 2003. Triangle Park, NC: GlaxoSmithKline, Research. Available at: http://pdr.net/pdrnet/librarian/NP_PR/DrugInfo/SBK. Last accessed July 6, 2004.
7. Azziz R., Ehrmann D., Legro R.S., Whitcomb R.W., Hanley R., Fereshetian A.G., et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 86 (2001) 1626-1632
8. Elkind-Hirsch K.E., and McWilliams R.B. Pregnancy after treatment with the insulin-sensitizing agent troglitazone in an obese woman with the hyperandrogenic, insulin-resistant acanthosis nigricans syndrome. Fertil Steril 71 (1999) 943-947
9. Cataldo N.A., Abbasi F., McLaughlin T.L., Lamendola C., and Reaven G.M. Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. Fertil Steril 76 (2001) 1057-1059
10. Baillargeon J.P., Jakubowicz D.J., Iuorno M.J., Jakubowicz S., and Nestler J.E. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 82 (2004) 893-902
11. Vandermolen D.T., Ratts V.S., Evans W.S., Stovall D.W., Kauma S.W., and Nestler J.E. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 75 (2001) 310-315
12. Mitwally M.F., Kuscu N.K., and Yalcinkaya T.M. High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome. Hum Reprod 14 (1999) 2700-2703
13. Ghazeeri G., Kutteh W.H., Bryer-Ash M., Haas D., and Ke R.W. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 79 (2003) 562-566
14. Clifford K., Rai R., Watson H., and Regan L. An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases. Hum Reprod 9 (1994) 1328-1332
15. Jakubowicz D.J., Iuorno M.J., Jakubowicz S., Roberts K.A., and Nestler J.E. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 87 (2002) 524-529
16. Liddell H.S., Sowden K., and Farquhar C.M. Recurrent miscarriage: screening for polycystic ovaries and subsequent pregnancy outcome. Aust NZ J Obstet Gynaecol 37 (1997) 402-406
17. Regan L., Braude P.R., and Trembath P.L. Influence of past reproductive performance on risk of spontaneous abortion. BMJ 299 (1989) 541-545
18. Sagle M., Bishop K., Ridley N., Alexander F.M., Michel M., Bonney R.C., et al. Recurrent early miscarriage and polycystic ovaries. BMJ 297 (1988) 1027-1028
19. Checa M.A., Requena A., Salvador C., Tur R., Callejo J., Espinos J.J., et al. Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome. Hum Reprod Update 11 (2005) 375-390
20. De Leo V., la Marca A., and Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 24 (2003) 633-667
21. Chan L.Y., Yeung J.H., and Lau T.K. Placental transfer of rosiglitazone in the first trimester of human pregnancy. Fertil Steril 83 (2005) 955-958
22. Bedaiwy M.A., Miller K.F., Goldberg J.M., Nelson D., and Falcone T. Effect of metformin on mouse embryo development. Fertil Steril 76 (2001) 1078-1079
23. Gardiner C.S., and Reed D.J. Status of glutathione during oxidant-induced oxidative stress in the preimplantation mouse embryo. Biol Reprod 51 (1994) 1307-1314
24. Rayburn W.F., Sienko A.E., Gonzalez C.L., Christensen H.D., Kupiec T.C., Paulsen A.L., et al. Impact of antenatal exposure of mice to fenfluramine on cardiac development and long-term growth of the offspring. Drug Chem Toxicol 23 (2000) 419-431
25. Ryan M.J., Didion S.P., Mathur S., Faraci F.M., and Sigmund C.D. PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 43 (2004) 661-666
26. Phillips J.W., Barringhaus K.G., Sanders J.M., Yang Z., Chen M., Hesselbacher S., et al. Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes. Circulation 108 (2003) 1994-1999
27. Cox P.J., Ryan D.A., Hollis F.J., Harris A.M., Miller A.K., Vousden M., et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 28 (2000) 772-780
28. Bernard B.K., Hoberman A.M., Brown W.R., Ranpuria A.K., and Christian M.S. Oral (gavage) two-generation (one litter per generation) reproduction study of pentachlorophenol (penta) in rats. Int J Toxicol 21 (2002) 301-318
29. Jagetia G.C., and Baliga M.S. Induction of developmental toxicity in mice treated with Alstonia scholaris (Sapthaparna) in utero. Birth Defects Res B Dev Reprod Toxicol 68 (2003) 472-478
30. Christensen H.D., Rayburn W.F., Parker K.M., Gonzalez C.L., and Gold K.P. Chronic prenatal exposure to carbamazepine and perinatal outcomes of C3H/He mice. Am J Obstet Gynecol 190 (2004) 259-263
31. Altman D. Practical statistics for medical research (1997), Chapman and Hall/CRC, London
32. Diggle P.J., Heagerty P., Liang K.Y., and Zeger S.L. Analysis of longitudinal data (2002), Oxford University Press, Wiley & Sons, Inc, New York
33. Kunstyr I. Paresis of peristalsis and ileus lead to death in lactating mice. Lab Anim 20 (1986) 32-35
34. Chen Y.E., Fu M., Zhang J., Zhu X., Lin Y., Akinbami M.A., et al. Peroxisome proliferator-activated receptors and the cardiovascular system. Vitam Horm 66 (2003) 157-188
35. Mohan M., Malayer J.R., Geisert R.D., and Morgan G.L. Expression patterns of retinoid X receptors, retinaldehyde dehydrogenase, and peroxisome proliferator activated receptor gamma in bovine preattachment embryos. Biol Reprod 66 (2002) 692-700
36. Jain S., Pulikuri S., Zhu Y., Qi C., Kanwar Y.S., Yeldandi A.V., et al. Differential expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse. Am J Pathol 153 (1998) 349-354
37. Li Q., Cheon Y.P., Kannan A., Shanker S., Bagchi I.C., and Bagchi M.K. A novel pathway involving progesterone receptor, 12/15-lipoxygenase-derived eicosanoids, and peroxisome proliferator-activated receptor gamma regulates implantation in mice. J Biol Chem 279 (2004) 11570-11581
38. Asami-Miyagishi R., Iseki S., Usui M., Uchida K., Kubo H., and Morita I. Expression and function of PPARgamma in rat placental development. Biochem Biophys Res Commun 315 (2004) 497-501
39. Kubota N., Terauchi Y., Miki H., Tamemoto H., Yamauchi T., Komeda K., et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4 (1999) 597-609
40. Barak Y., Nelson M.C., Ong E.S., Jones Y.Z., Ruiz-Lozano P., Chien K.R., et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 4 (1999) 585-595
41. Schaiff W.T., Bildirici I., Cheong M., Chern P.L., Nelson D.M., and Sadovsky Y. Peroxisome proliferator-activated receptor-gamma and retinoid X receptor signaling regulate fatty acid uptake by primary human placental trophoblasts. J Clin Endocrinol Metab 90 (2005) 4267-4275
42. Fournier T., Pavan L., Tarrade A., Schoonjans K., Auwerx J., Rochette-Egly C., et al. The role of PPAR-gamma/RXR-alpha heterodimers in the regulation of human trophoblast invasion. Ann NY Acad Sci 973 (2002) 26-30
43. Sandor T.L., Noll L., Klinkner D.B., Weihrauch D., He B.J., Kaul S., et al. Rosiglitazone antagonizes VEGF signalling and NFATc1 activation in cardiac valve endothelium. Endothelium 13 (2006) 181-190
44. Berry E.B., Eykholt R., Helliwell R.J., Gilmour R.S., Mitchell M.D., and Marvin K.W. Peroxisome proliferator-activated receptor isoform expression changes in human gestational tissues with labor at term. Mol Pharmacol 64 (2003) 1586-1590
45. Lappas M., Permezel M., Georgiou H.M., and Rice G.E. Regulation of proinflammatory cytokines in human gestational tissues by peroxisome proliferator-activated receptor-gamma: effect of 15-deoxy-Delta(12,14)-PGJ(2) and troglitazone. J Clin Endocrinol Metab 87 (2002) 4667-4672
46. Kalyoncu N.I., Yaris F., Ulku C., Kadioglu M., Kesim M., Unsal M., et al. A case of rosiglitazone exposure in the second trimester of pregnancy. Reprod Toxicol 19 (2005) 563-564
47. Vaughan T.B., and Bell D.S. Stockpiling of ovarian follicles and the response to rosiglitazone. Diabetes Care 28 (2005) 2333-2334
48. Yaris F., Yaris E., Kadioglu M., Ulku C., Kesim M., and Kalyoncu N.I. Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman. Reprod Toxicol 18 (2004) 619-621
49. Leiter E.H., Reifsnyder P.C., Zhang W., Pan H.J., Xiao Q., and Mistry J. Differential endocrine responses to rosiglitazone therapy in new mouse models of type 2 diabetes. Endocrinology 147 (2006) 919-926